Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $3.5 million.

  • Stoke Therapeutics' Non Operating Income fell 299.47% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 1287.35%. This contributed to the annual value of $12.4 million for FY2024, which is 2299.98% up from last year.
  • Per Stoke Therapeutics' latest filing, its Non Operating Income stood at $3.5 million for Q3 2025, which was down 299.47% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Non Operating Income ranged from a high of $3.8 million in Q2 2025 and a low of $146000.0 during Q1 2022
  • For the 4-year period, Stoke Therapeutics' Non Operating Income averaged around $2.4 million, with its median value being $2.6 million (2023).
  • In the last 5 years, Stoke Therapeutics' Non Operating Income surged by 136917.81% in 2023 and then tumbled by 685.31% in 2024.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Non Operating Income stood at $1.5 million in 2022, then surged by 72.78% to $2.6 million in 2023, then rose by 20.66% to $3.2 million in 2024, then grew by 9.3% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $3.8 million for Q2 2025, and $2.9 million during Q1 2025.